Finding new treatments and understanding how congenital glycosylation disorders work
Official title: Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
Funded at University of Kansas Lawrence · NIH-11406266 · Data updated 2026-11-12
A research project aims to uncover how certain congenital glycosylation disorders develop and identify existing drugs that could help treat DPAGT1-CDG.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Lawrence NIH-funded |
| Lab location | 1 site (Lawrence, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $238,616 |
| NIH project number | 5R00HD111662-05 |
| Project ID | NIH-11406266 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with DPAGT1-CDG or related congenital disorders of glycosylation could benefit if the identified targets or drugs progress to clinical testing.
✕Less likely to help
Individuals without DPAGT1-CDG or related CDGs are unlikely to directly benefit from this basic-to-translational study.
What this research studies
This project uses human cell models to study how modifier genes influence DPAGT1-CDG and affect cell growth, stress responses, and the glycoprotein makeup of cells. It also includes an in vivo screen in fruit flies to test hundreds of approved drugs for their ability to rescue the disease features, with the goal of speeding up potential therapies for patients. The work combines cellular experiments with a large drug screen to pinpoint promising treatment strategies that could move toward clinical testing. The focus is on translating basic discoveries into practical therapeutic options for people affected by DPAGT1-CDG and related CDGs.
Why it matters
Potential benefit: If successful, the project could reveal new therapeutic targets and identify approved drugs that might be repurposed to help patients with DPAGT1-CDG.
How similar studies have gone: Previous research in this area has shown that modifying pathways can rescue disease models, but translating these findings to human patients remains challenging and ongoing.
Where this research is happening
-
University of Kansas Lawrence
Lawrence, United States Active
Researchers
- Principal investigator: Dalton, Hans Martin — University of Kansas Lawrence
- Study coordinator: Dalton, Hans Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.